Table 2.
Tumor characteristics of the eligible studies
| Study | Staging system | Grading system | TN+/TN- | Stage 1–2/ 3–4 | Grade 1–2/ 3–4 | ccRCC/no-ccRCC | Tumor size (cm) |
|---|---|---|---|---|---|---|---|
| Xia et al.2017 [12] | 2010 AJCC | Furman | 41/252 | 212/81 | 248/45 | 293/0 | NA |
| Wu et al.2017 [13] | 2010 AJCC | Furman | 77/224 | 265/36 | 225/76 | 301/0 | NA |
| Niu et al.2017 [14] | 2010 AJCC | Furman | 75/309 | 295/89 | 255/129 | 384/0 | Mean ± SD 4.1 ± 2.1 |
| Kim et al.2017 [15] | 2009 AJCC | Furman | 46/131 | 60/82 | 44/105 | 159/3 | Median (range) 8 (1–117) |
| Gu et al.2017 [16] | 2010 AJCC | Furman | 90/94 | NA | 70/94 | 161/23 | NA |
| Gershman et al.2017 [17] | 2010 AJCC | WHO/ ISUP | 111/27 | 31/106 | 6/132 | 105/33 | Median (range) 10(8–13) |
| Chen et al.2017 [18] | 2010 AJCC | Furman | 53/110 | 0/163 | 83/55 | 135/8 | Mean ± SD 6.8 ± 3.5 |
| Chang1 et al.2016 [19] | 2010 AJCC | Furman | 182/51 | 169/64 | 135/96 | 233/0 | NA |
| Volpe et al.2016 [3] | 2002 AJCC | Furman | 60/130 | 190/0 | 155/35 | 156/34 | Median (IQR) 4.9(3.5–7) |
| Khor et al.2016 [20] | 2010 AJCC | Furman | 665/177 | 630/212 | 265/577 | 842/0 | Median (range) 4.2(0.6–20) |
| NguyenHoang et al.2016 [21] | 2010 AJCC | Furman | 78/294 | 292/100 | 259/133 | 392/0 | Mean ± SD 4.3 ± 2.6 |
| Errarte et al.2016 [22] | 2010 AJCC | Furman | 30/29 | 32/27 | 24/35 | 59/0 | Median (range) 7.9(2–19) |
| Byun et al.2016 [23] | 2002 AJCC | Furman | 208/1076 | 1105/179 | 664/620 | 1114/170 | Mean ± SD 4.08 ± 2.68 |
| Huang et al.2015 [24] | 2010 AJCC | Furman | 34/184 | 160/58 | 155/63 | 0/218 | Median (IQR) 3.5(2.5–6) |
| Cornejo et al.2015 [25] | NA | Fuhrman/ ISUP | 40/114 | 121/33 | 103/51 | 0/154 | Mean (range) 5.1(0.4–17) |
| Teng et al.2014 [26] | 2009 AJCC | Furman | 38/340 | 346/32 | 200/178 | 378/0 | Mean ± SD 4.6 ± 2.6 |
| Park et al.2014 [27] | NA | Furman | 37/46 | NA | 13/70 | 83/0 | NA |
| Oliveira et al.2014 [28] | 2010 AJCC | Furman | 18/76 | 77/17 | 65/29 | 94/0 | Mean ± SD 4.7 ± 2.6 |
| Can et al.2014 [29] | 2010 AJCC | Furman | 42/85 | 84/43 | 72/55 | 127/0 | NA |
| Pichler et al.2013 [30] | 2010 AJCC | Furman | 277/717 | 723/271 | 839 | 804/190 | NA |
| Kruck et al.2013 [31] | 2010 AJCC | Furman | 114/164 | 169/109 | 234/44 | 278/0 | Mean ± SD 5.26 ± 2.91 |
| Fukatsu et al.2013 [32] | 2010 AJCC | Furman | 57/104 | 508/53 | 341/220 | 561/0 | NA |
| Sukov et al.2013 [33] | 2010 AJCC | Furman | 186/209 | 346/49 | 247/148 | 0/395 | NA |
| Chang2 et al.2011 [34] | 2002 AJCC | Furman | 139/189 | 240/88 | 216/112 | 232/96 | NA |
| Leibovich et al.2010 [35] | 2002 AJCC | Furman | 792/2090 | 1992/1070 | 1649/1413 | 1781/1281 | NA |
| Katz et al.2010 [36] | 2002 AJCC | Furman | 253/586 | 575/194 | 589/252 | 641/198 | NA |
| Roos et al.2009 [37] | 2002 AJCC | Furman | 10/108 | 0/118 | 63/55 | 109/16 | Median (range) 8(2.5–20) |
| Coons et al.2009 [38] | 2002 AJCC | Furman | 57/71 | 0/128 | 40/103 | 105/23 | Median (range) 9.9 (3.5–21) |
| Pflanz et al.2008 [39] | 2002WHO | Thoenes | 155/452 | 515/92 | 532/75 | 479/128 | NA |
| Lee et al.2006 [40] | 1997 AJCC | Furman | 131/354 | 382/103 | 364/221 | 419/66 | NA |
| Lam et al.2005 [41] | 1997 AJCC | Fuhrman | 168/143 | 157/153 | 186/119 | 270/41 | NA |
| Tornberg et al.2016 [42] | 2009 AJCC | Furman | 84/58 | 0/132 | 38/104 | 129/13 | Mean ± SD 10.3 ± 3.6 |
| Schiavina et al.2015 [43] | 2009 AJCC | Furman | 49/136 | 0/185 | 46/139 | 150/35 | Mean ± SD 8.05 ± 2.8 |
| Ramsey et al.2008 [44] | 1997 AJCC | Furman | 55/28 | 48/35 | 37/40 | 33/50 | NA |
total numbers rows:36; TN+/TN tumor necrosis positive/ tumor necrosis negative, SD standard deviation, NA data not applicable, ccRCC/no-ccRCC clear cell renal cell carcinoma/non- clear cell renal cell carcinoma